Evolent Health, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Evolent Health raised FY2026 revenue guidance to $2.6–$2.7B (from prior range) and tightened Adjusted EBITDA to $120–$135M. Q2 2026 revenue was $652.5M (up 47% YoY from $444.3M); net loss improved to $(28.4)M (vs. $(51.1)M YoY) on net loss margin of (4.3)% (vs. (11.5)%). Two major partnership announcements: (1) Oncology Performance Suite covering ~1.5M lives across Medicaid/Medicare in 11 states, launching by December 2026, expected to generate ~$300M annualized revenue; (2) Blues plan Specialty Tech expansion adding <$5M annualized revenue. Medical Expense Ratio deteriorated to 95.3% (vs. 80.0% YoY), signaling margin pressure despite strong top-line growth.
Why this rating
Large absolute revenue growth ($300M oncology deal) and positive guidance raise; however, MER spike, net loss persistence, margin compression (Adj EBITDA margin fell 4.2 pts YoY to 4.3%), and $966M debt v. $1.3B market cap pose material headwinds. Meaningful but offset by profitability concerns.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.